Aligos Therapeutics (ALGS) Change in Accured Expenses (2019 - 2026)

Aligos Therapeutics has reported Change in Accured Expenses for 8 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 67.74% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 188.47% YoY), and the FY2025 full-year result was -$2.0 million, down 46.33% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from -$79000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $11.4 million in Q4 2022, with the low at -$12.4 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged -$245352.9 across 5 years, with a median of $1000.0 in 2022.
• The largest YoY upside for Change in Accured Expenses was 89600.0% in 2022 against a maximum downside of 1242500.0% in 2022.
• Aligos Therapeutics' Change in Accured Expenses stood at $11.4 million in 2022, then slumped by 59.85% to $4.6 million in 2023, then plunged by 71.74% to $1.3 million in 2024, then sank by 106.11% to -$79000.0 in 2025, then sank by 1845.57% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), -$79000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.